BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

Point mutations in the kinase domain of BCR-ABL are the most common mechanism of drug resistance in chronic myeloid leukemia (CML) patients treated with ABL kinase inhibitors, including imatinib. It has also been shown in vitro that mutations outside the kinase domain in the neighboring linker, SH2,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sherbenou, Daniel W., Hantschel, Oliver, Kaupe, Ines, Willis, Stephanie, Bumm, Thomas, Turaga, Lalita P., Lange, Thoralf, Dao, Kim-Hien, Press, Richard D., Druker, Brian J., Superti-Furga, Giulio, Deininger, Michael W.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2010
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2995357/
https://ncbi.nlm.nih.gov/pubmed/20519627
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-10-183665
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados